Figure 25 displays a forest plot for the network meta-analysis reporting discontinuations due to adverse events in studies comparing MTX plus Non-TNF biologics with Non-TNF biologics alone. Two comparisons were used in this analysis. Study-level data used in this Figure are presented in Appendix C. This figure is described further in the KQ3 Results section “csDMARDs Versus Biologics” as follows: “NWMA also examined ABA plus MTX and found no significant differences in overall discontinuations but fewer discontinuations due to adverse events for ABA plus MTX than ABA monotherapy (RR, 0.34; 95% CI, 0.18 to 0.64)”.

Figure 25Forest plot for network meta-analysis of discontinuations due to adverse events: Non-TNF + MTX versus non-TNF

95% CI = 95% confidence interval; MTX = methotrexate; RR = relative risk; TNF = tumor necrosis factor; vs. = versus.

From: Results

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.